drugset / Trial / NCT02047747
A Phase II Study of Dacomitinib in Progressive Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the disease response, survival, and side effects of an experimental drug called dacomitinib in progressive brain metastases.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 45 mg | Oral |